Optimer Pharmaceuticals Reports Third Quarter 2009 Financi...(Interest income and other net ...)

Date:11/3/2009

Interest income and other, net 33,935 411,352 308,973 1,426,386 ------ ------- ------- --------- Net loss $(9,406,247) $(9,188,183) $(32,655,640) $(25,181,525) =========== =========== ============ ============ Basic and diluted net loss per share $(0.28) $(0.31) $(1.01) $(0.89) ====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 33,103,345 29,253,693 32,250,194 28,377,733 ========== ========== ========== ========== Optimer Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2009 2008 ---- ---- (unaudited) ASSETS Current assets: Cash and cash equivalents $19,240,782 $16,778,880 Short-term investments 23,243,958 22,547,515 Prepaid expenses and other current assets 579,134 744,670 ------- ------- Total current assets 43,063,874 40,071,065 Property and equipment, net 697,328 694,183 Long-term investments 882,000 1,032,000 Other assets 498,644 498,250 ------- ------- Total assets $45,141,846 $42,295,498
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009